{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    9,
    11,
    13,
    19,
    23,
    39,
    41,
    46,
    48,
    51,
    59
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Endpoints Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.2.4",
        "sectionTitle": "Efficacy Endpoint Definitions",
        "description": "Reference for definitions of endpoints used in induction and maintenance studies"
      },
      {
        "id": "ref_2",
        "name": "Futility Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "11.11.1",
        "sectionTitle": "Interim Analysis: Induction Study",
        "description": "Reference for details on the independent Data Monitoring Committee's role in futility analysis"
      },
      {
        "id": "ref_3",
        "name": "DMC Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "11.12",
        "sectionTitle": "Data Monitoring Committee",
        "description": "Reference for further details on the Data Monitoring Committee"
      },
      {
        "id": "ref_4",
        "name": "Maintenance Study Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.2",
        "sectionTitle": "Maintenance Study",
        "description": "Reference for eligibility to enter the maintenance study after Week 16 re-evaluation"
      },
      {
        "id": "ref_5",
        "name": "Induction Therapy Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Induction Study",
        "description": "Reference for discontinuation or reduction of UC-specific medical therapies"
      },
      {
        "id": "ref_6",
        "name": "Restricted Therapy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1.1",
        "sectionTitle": "Restricted or Prohibited Medications/Therapies",
        "description": "Reference for prohibited medications that prevent entry into the maintenance study"
      },
      {
        "id": "ref_7",
        "name": "Corticosteroid Taper Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.2",
        "sectionTitle": "Maintenance Study",
        "description": "Reference for details on corticosteroid tapering in the maintenance study"
      },
      {
        "id": "ref_8",
        "name": "Clinical Flare Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.4.1",
        "sectionTitle": "Management of Clinical Flare and Loss of Response",
        "description": "Reference for criteria used to define clinical flare"
      },
      {
        "id": "ref_9",
        "name": "Rescue Medication Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.2.1",
        "sectionTitle": "Rescue Medication on Loss of Response",
        "description": "Reference for eligible rescue medications after loss of response"
      },
      {
        "id": "ref_10",
        "name": "Biologic Failure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Attachment 1",
        "sectionTitle": "Biologic Therapy Failure",
        "description": "Reference for history of failure to respond to biologic therapy"
      },
      {
        "id": "ref_11",
        "name": "Corticosteroid Response Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Attachment 2",
        "sectionTitle": "Corticosteroid/Immunomodulator Response",
        "description": "Reference for definitions of inadequate response to corticosteroids or immunomodulators"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Janssen Research & Development is a global organization that operates through different legal entities in various countries.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "The term 'sponsor' used throughout this document refers to the entities listed in the Contact Information page(s).",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "1. Introduction",
        "pageNumber": 40
      },
      {
        "id": "annot_3",
        "text": "All subjects will undergo QuantiFERON-TB Gold testing. In countries where not approved, TB skin testing is required (recommended but not required in Ukraine if tuberculin is unavailable).",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Time and Events Schedule: Induction Study",
        "pageNumber": 8
      },
      {
        "id": "annot_4",
        "text": "Vital signs include temperature, pulse/heart rate, respiratory rate, and blood pressure.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.7 Safety Evaluations",
        "pageNumber": 10
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-03-17",
        "description": "Original Protocol",
        "amendmentNumber": "N/A"
      },
      {
        "id": "ver_2",
        "versionNumber": "Amendment 1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-07-14",
        "description": "Substantial amendment to address health authority feedback and clarify maintenance dosing.",
        "amendmentNumber": "1"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 2",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-04-20",
        "description": "Substantial amendment to address health authority requests for additional data collection (Bristol Stool Form Scale) and clarify US-specific remission definitions.",
        "amendmentNumber": "2"
      }
    ],
    "summary": {
      "referenceCount": 11,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}